Literature DB >> 22234527

Prevalence of monoclonal gammopathy of undetermined significance in Thailand.

Phandee Watanaboonyongcharoen1, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin, Panisinee Lawasut, Tanin Intragumtornchai.   

Abstract

Individuals with monoclonal gammopathy of undetermined significance (MGUS) develop multiple myeloma and related malignancies at the rate of 1% per year. Given differences in ethnicity, data on prevalence and risk factors of MGUS in Thai population will be helpful in understanding the pathogenesis of plasma cell disorders and designing an early cancer detection strategy. Subjects of 50 years or older were included. Demographic data and suspected risk factors were collected. Monoclonal proteins were detected using serum protein electrophoresis. Serum was obtained from 3,260 participants; 1,104 males (33.9%) and 2,156 females (66.1%). The median age was 57 years (range 50-93 years). Monoclonal proteins were detectable in 2.3% (95% confidence interval [CI] 1.8-2.8). M spikes were found in gamma- and beta-globulin regions in 50 (1.5%) and 25 (0.8%) subjects, respectively. The prevalence of MGUS in subjects 50-59, 60-69, and 70 years or older was 2.0% (41/1,975), 2.6% (22/851), and 2.8% (12/434), respectively. By multivariate analysis, MGUS was associated with living outside Bangkok (odds ratio 2.25, 95% CI 1.11-4.58). The overall prevalence of MGUS in the Thai population was 2.3%, which was lower than that in Western countries, but comparable to that in Japan.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234527     DOI: 10.1007/s12185-011-0995-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies.

Authors:  Nikhil C Munshi
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

Review 3.  Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.

Authors:  O Landgren; B M Weiss
Journal:  Leukemia       Date:  2009-07-09       Impact factor: 11.528

4.  Monoclonal gammopathy in Iceland: a population-based registry and follow-up.

Authors:  Helga M Ogmundsdóttir; Vilhelmína Haraldsdóttir; Guethmundur M Jóhannesson; Guethríethur Olafsdóttir; Kristín Bjarnadóttir; Helgi Sigvaldason; Hrafn Tulinius
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

5.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 6.  Epidemiology of the plasma-cell disorders.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

7.  Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance.

Authors:  Azhar A Malik; Apar Kishor Ganti; Anil Potti; Ralph Levitt; James F Hanley
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

8.  Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese.

Authors:  Li-Na Lee; I-Shiow Jan; Hwei-Fang Tien; Jen-Shiou Lin; Shyh-Chyi Lo; Wern-Cherng Cheng
Journal:  J Formos Med Assoc       Date:  2002-02       Impact factor: 3.282

9.  Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.

Authors:  Masako Iwanaga; Masuko Tagawa; Kunihiro Tsukasaki; Tatsuki Matsuo; Ken-ichi Yokota; Yasushi Miyazaki; Takuya Fukushima; Tomoko Hata; Yoshitaka Imaizumi; Daisuke Imanishi; Jun Taguchi; Sabro Momita; Shimeru Kamihira; Masao Tomonaga
Journal:  Blood       Date:  2008-10-10       Impact factor: 22.113

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

View more
  8 in total

1.  On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Guillermo J Ruiz-Argüelles; Guillermo J Ruiz-Delgado
Journal:  Int J Hematol       Date:  2012-06-03       Impact factor: 2.490

2.  MGUS prevalence in an ethnically Chinese population in Hong Kong.

Authors:  S Peter Wu; Alex Minter; Rene Costello; Adriana Zingone; Cheuk-Kwong Lee; Wing-Yan Au; Ola Landgren
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

Review 3.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

4.  Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.

Authors:  Benjamin M Cherry; Rene Costello; Adriana Zingone; Jason Burris; Neha Korde; Elisabet Manasanch; Mary Kwok; Christina Annunziata; Mark J Roschewski; Eric A Engels; Ola Landgren
Journal:  Am J Hematol       Date:  2012-11-21       Impact factor: 10.047

Review 5.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

6.  Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.

Authors:  Theodóra Rún Baldursdóttir; Þorvarður Jón Löve; Gauti Kjartan Gíslason; Magnus Björkholm; Ulf-Henrik Mellqvist; Sigrun Helga Lund; Cecilie Hveding Blimark; Ingemar Turesson; Malin Hultcrantz; Ola Landgren; Sigurður Yngvi Kristinsson
Journal:  Eur J Haematol       Date:  2020-12-28       Impact factor: 3.674

7.  Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.

Authors:  Ling Ma; Shuang Xu; Jianhua Qu; Jian Hou; Yang Wang; Lei Wen; Yang Liu; Ying Kang; Ming Jiang; Weijun Fu; Juan Du; Lin Zhou; Xiaojun Huang; Zhaoxia Zhang; Jin Lu
Journal:  Hematol Oncol       Date:  2018-10-01       Impact factor: 5.271

8.  A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea.

Authors:  Ka-Won Kang; Ji Eun Song; Byung-Hyun Lee; Min Ji Jeon; Eun Sang Yu; Dae Sik Kim; Se Ryeon Lee; Hwa Jung Sung; Chul Won Choi; Yong Park; Byung Soo Kim
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.